Biogen provides a range of resources to support the educational development of MS healthcare professionals.
Shed Light on MS
Shed Light on MS aims to show the value of MRI as a tool, both for diagnosis and monitoring in multiple sclerosis, through hypothetical patient case studies, as well as information on how MRI should be used.
Using MRI as a clinical tool for MS prognosis is becoming increasingly possible. This was highlighted by the 2015 MAGNIMS (Magnetic Resonance Imaging in MS) Consensus Statement, which discussed various avenues of research in this area1. While the value of MRI for diagnosis is recognised, its use in monitoring disease progression and treatment effectiveness has been overlooked until recently1.
The importance of MRI as a tool for monitoring the MS disease course was brought into focus by inclusion of annual MRI scanning in the first EAN/ECTRIMS guidelines2. This move signified official recognition of proactive monitoring for “clinically silent” disease activity as the standard of care.
Neuro-Knowledge Educational Modules
Bite-sized educational modules that can support your Continuing Professional Development or revalidation. Based on expert presentations at recent meetings, each module can be completed in around 15-minutes, some with accompanying speaker videos. Complete the reflective learning notes pre and post-module for your own records and test your knowledge at the end of each module.
Duty of Candour & Consent
This webinar recording supports healthcare professionals with patient dialogue in the increasingly complex therapeutic area of MS, where it is of utmost importance that patients understand the benefits and risks of any treatment they consent to taking.
Dr Adam Wolverson and Shannon Gaughan from United Lincolnshire Hospitals NHS Trust provide a useful and concise update for anyone responsible for patient care and prescribing for people with MS.
Learning objectives and reflective learning questions are provided to support your continuing professional development.
Why treatment choice matters in MS
With a wide-range of different disease modifying treatments (DMTs) available, each with distinct mechanisms of action, efficacy and safety profiles, monitoring requirements and administration or dosing considerations, it is important that healthcare professionals consider the right treatment for the right patient at the right time. Known as sequencing, different DMTs may be required at different times throughout a patient's lifetime and may affect which products may be used next.
Biogen is committed to furthering our collective knowledge of Multiple Sclerosis (MS). This applies to the disease area in general, as well as providing up to date, fair, accurate and balanced information on our medicines to support their appropriate use. Biogen’s Real-World Evidence (RWE) programme aims to fill knowledge gaps and build a wider, more complete picture of our medicines’ effectiveness, and MS in general, beyond the randomised clinical trial setting.
1. Wattjes MP, Rovira A Miller D, et al. MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis - establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11:597-606.
2. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. J Neurol 2018; 25: 215-237.